Direct Thrombin Inhibition with Rec-Hirudin CGP 39393 as Prophylaxis of Thromboembolie Complications after Total Hip Replacement

Summary

Hirudin is an anticoagulant originally extracted from the leech Hirudo medicinalis. Using recombinant DNA technology a new compound, recombinant desulphato hirudin CGP 39393 has now been produced. The aim of this study was to determine the maximum tolerated dose in patients undergoing elective hip replacement. This open safety trial represents, to our knowledge, the first experience of recombinant hirudin in orthopedic patients.

In this study 48 patients undergoing primary total hip replacement were included and the safety of subcutaneous injections of 10, 15, 20 and 40 mg CGP 39393 twice daily, was evaluated. Prophylaxis was started immediately pre-operatively and continued for 8-10 days. A mandatory bilateral phlebography was performed at the end of the prophylactic treatment period and a clinical follow-up was done 6 weeks after surgery.

A major bleeding event occurred in the first 3 patients receiving 40 mg CGP 39393 b.i.d. and the prophylaxis regimen at this dosage level was therefore discontinued. Median values of total blood loss and requirements of blood transfusion in the patients receiving 10-20 mg CGP 39393 were similar to those reported in previous studies on total hip replacement performed at the same centre, using other prophylactic drugs. Deep vein thrombosis (DVT) was confirmed by phlebography in 5 out of 12 patients in the 10 mg group (41.7%, 95% confidence limits [CL]: 15.2-72.3%), 1 out of 11 patients in the 15 mg group (9.1%, CL: 0.23-41.3%) and 2 out of 20 patients in the 20 mg group (10.0%, CL: 1.2-31.7%) during the prophylaxis period.

CGP 39393 was safe and well tolerated, when administered as subcutaneous injections of 10-20 mg twice daily. The dose level of 40 mg CGP 39393 twice daily resulted in serious disturbance of the hemostasis in patients after hip prosthesis surgery.

• References

• 1 Markwardt F, Hauptmann J, Nowak G, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226-229
• 2 Ishikawa A, Hafter R, Seemüller U, Gokel J, Graeff H. The effect of hirudin on endotoxin induced disseminated intravascular coagulation (DIC). Thromb Res 1980; 19: 351-358
• 3 Bucha E, Nowak G, Markwardt F. Prevention of experimental coronary thrombosis by hidurin. Folia Haematol 1988; 115: 52-58
• 4 Hauptmann J, Bruggener E, Markwardt F. Effect of heparin, hirudin and a synthetic thrombin inhibitor on antithrombin III in thrombin-induced disseminated intravascular coagulation in rats. Haemostasis 1987; 17: 321-328
• 5 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res 1986; 43: 613-620
• 6 Markwardt F. The comeback of hirudin an old established anticoagulant agent. Folia Haematol (Leipz) 1988; 115: 10-23
• 7 Hoet B, Close P, Vermylene J, Verstraete M. Hirudo medicinalis and hirudin. In: Recent advances in blood coagulation Poller L. (ed) Edinburgh, London, Melbourne, New York : Churchill Livingstone; 1991: 223-244
• 8 Markwardt F, Nowak G, Stiirzebecker J, Griessbach U, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984; 52: 160-163
• 9 Bichler J, Fichtl B, Siebeck M, Fritze H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Drug Res 1988; 38: 704-710
• 10 Close P, Meyer D, Tsakiris DA, Graf P, Marbet GA. Effects of a recombinant hirudin infusion on ex-vivo coagulation and platelet function tests in healthy volunteers. Abstract 2093. Eur Heart J 1990; 11: 385
• 11 Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, Silling-Engelhardt G, Close P. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharm 1993; 22: 364-372
• 12 Verstraete M, Nurmohamed M, Kienast J. et al Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. JACC 1993; 22: 1080-1088
• 13 Eriksson BI, Kälebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement. Comparison of a low molecular weight heparin and unfractionated heparin J Bone Joint Surg 1991; 73A: 479-489
• 14 Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, Elliott C, Panju A, Brant R. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium forprophylaxis against deep-vein thrombosis after hip or knee implantation. New England J Med 1993; 329: 1370-1376
• 15 Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briët E. Low-molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156
• 16 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
• 17 Borgström S, Greitz T, van den Linden W, Molin J, Rudies I. Ascending phlebography in fresh thrombosis of the lower limb. AJR 1965; 94: 207-212
• 18 Zachrisson BE, Jansen H. Phlebographic signs of fresh postoperative venous thrombosis of the lower extremity. Acta Radiol Diagn 1973; 14: 81-96
• 19 Kälebo P, Anthmyr BA, Eriksson BI. Zacharisson BE. Phlebographic signs of venous thrombosis after total hip replacement. Acta Radiol 1990; 31: 259-263
• 20 Biello DR, Mattar AG, McKnight RC, Siegel BA. Ventilation-perfusion studies in suspected pulmonary embolism. AJR 1979; 133: 1033-1037
• 21 Hartung J, Statistik S. Lehrbuch und Handbuch der angewandten Statistik. Oldenburg Verlag 1984
• 22 Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg 1988; 75: 1053-1057